Business
Prelim Results for the year ended 30 April 2019
Prelim Results for the year ended 30 April 2019.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 2747H Angle PLC 31 July 2019 \n\n\n\n\nFor Immediate Release \n\n\n31 July 2019\n\n\n\n \nANGLE plc\n(\"ANGLE\" or \"the Company\")\n \nPreliminary Results for the year ended 30 April 2019\n \nBUILDING ON A LEADING POSITION IN THE LIQUID BIOPSY MARKET\n \n FDA SUBMISSION ON TRACK FOLLOWING POSITIVE RESULTS FROM BREAST CANCER CLINICAL STUDY\n \n \nANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, today announces unaudited results for the year ended 30 April 2019. \n \nOperational Highlights\n \n· 400 subject FDA clinical study enrolment using the Parsortix® system in metastatic breast cancer completed by four leading US cancer centres with positive primary and exploratory objectives announced post period end, a key milestone for the Company. FDA submission on track and expected early Q4 CY19\n \n· Extensive optimisation of HyCEADTM Ziplex® molecular analysis platform successfully completed, demonstrating exceptionally high sensitivity enabling the detection and characterisation of as low as a single cancer cell\n \n· Ovarian cancer clinical verification study established with leading US cancer centre. Pre-study phase completed successfully; 200 subject study expected to start in Q3 CY19\n \n· Leveraged partnership strategy delivers further validation, new uses and commercial progress with key developments in circulating tumour cell clusters\n \n· 24,000 blood samples processed during the year (2018: 19,000) and an installed base of c.200 Parsortix instruments has led to a growing body of published evidence from internationally recognised cancer centres, with a further 10 peer reviewed publications during the year (2018: 6) \n \n \nFinancial Highlights\n \n· Loss for the year £8.9 million (2018: loss £7.5 million) reflecting planned investment\n \n· Revenue and grant income £0.9 million (2018: £0.7 million)\n \n· Cash balance at 30 April 2019 of £11.0 million (30 April 2018: £7.6 million)\n \n· Post year end fundraising of £18.0 million (£16.9 million net of expenses)\n \n \nGarth Selvey, Non-Executive Chairman of AN...